These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36635710)

  • 1. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
    Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
    J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
    Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
    J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer.
    Zhu W; Zeng H; Huang J; Wu J; Wang Y; Wang Z; Wang H; Luo Y; Lai W
    J Transl Med; 2023 Nov; 21(1):782. PubMed ID: 37925432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches.
    Wang Y; Ji B; Zhang L; Wang J; He J; Ding B; Ren M
    Biol Direct; 2024 Jun; 19(1):50. PubMed ID: 38918844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.
    Chen L; Zheng Y; Jiang C; Yang C; Zhang L; Liang C
    Front Immunol; 2022; 13():1009634. PubMed ID: 36275733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Machine Learning Method for Predicting Biomarkers Associated with Prostate Cancer.
    Tong Y; Tan Z; Wang P; Gao X
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):333. PubMed ID: 38179769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting prostate cancer recurrence: Introducing PCRPS, an advanced online web server.
    He X; Hu S; Wang C; Yang Y; Li Z; Zeng M; Song G; Li Y; Lu Q
    Heliyon; 2024 Apr; 10(7):e28878. PubMed ID: 38623253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
    Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
    Front Immunol; 2022; 13():982628. PubMed ID: 36325340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
    Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
    Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine-learning predicts time-series prognosis factors in metastatic prostate cancer patients treated with androgen deprivation therapy.
    Saito S; Sakamoto S; Higuchi K; Sato K; Zhao X; Wakai K; Kanesaka M; Kamada S; Takeuchi N; Sazuka T; Imamura Y; Anzai N; Ichikawa T; Kawakami E
    Sci Rep; 2023 Apr; 13(1):6325. PubMed ID: 37072487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
    Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC
    Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine learning-derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer.
    Huan Q; Cheng S; Ma HF; Zhao M; Chen Y; Yuan X
    J Cell Mol Med; 2024 Jan; 28(1):e18021. PubMed ID: 37994489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.
    Nishiyama T
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):179-90. PubMed ID: 22269996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternations of gene expression in PI3K and AR pathways and DNA methylation features contribute to metastasis of prostate cancer.
    Zhao Y; Hu X; Yu H; Liu X; Sun H; Shao C
    Cell Mol Life Sci; 2022 Jul; 79(8):436. PubMed ID: 35864178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
    Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
    J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts.
    Li R; Zhu J; Zhong WD; Jia Z
    Cancer Res; 2022 May; 82(9):1832-1843. PubMed ID: 35358302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.